Pubmed publications written by Dermatology Research and Education Foundation™ (updated October 11, 2020):
1. Wu JJ, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Arikan D, Fleischer A, Guérin A, Ganguli A. Adverse medical conditions across treatment options in patients with psoriasis: a claims-based analysis. Journal of Drugs in Dermatology, November 2018;17(11):1211-1218. PMID: 30500143.
2. Lee EB, Wu KK, Lee MP, Bhutani T, Wu JJ. Psoriasis risk factors and triggers. Cutis, November 2018;102(5S):18-20. PMID: 30566552.
3. Lee EB, Reynolds KA, Pithadia DJ, Wu JJ. Appearance of lentigines in psoriasis patient treated with guselkumab. Dermatology Online Journal, January 2019;25(1). PMID: 30710906.
4. Lee EB, Amin M, Duan L, Egeberg A, Wu JJ. Risk for appendicitis, cholecystitis, or diverticulitis in patients with psoriasis. Cutis, March 2019;103(3):175-179;E1;E2. PMID: 31039227.
5. Reynolds KA, Pithadia DJ, Lee EB, Wu JJ. A cross-sectional study of YouTube videos about psoriasis biologics. International Journal of Dermatology, March 2019;58(3):e61-e62. PMID: 30478827.
6. Strober BE, van der Walt JM, Armstrong AW, Boucier M, Carvalho AV, Chouela E, Cohen AD, Cruz C, Ellis CN, Finlay AY, Gottlieb AB, Gudjonsson JE, Iversen L, Kleyn CE, Leonardi CL, Lynde CW, Ryan C, Theng CT, Valenzuela F, Vender R, Wu JJ, Young HS, Kimball AB. Clinical goals and barriers to effective psoriasis care. Dermatology and Therapy, March 2019;9(1):5-18. PMID: 30578464.
7. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, April 2019;80(4):1029-1072. PMID: 30772098.
8. Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology, April 2019;80(4):1073-1113. PMID: 30772097.
9. Wu JJ, Pelletier C, Ung B, Tian M. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis. Journal of Medical Economics, April 2019;22(4):365-371. PMID: 30652520.
10. Lee EB, Wu JJ. Safety of long-term IL-23 inhibition in psoriasis patients. British Journal of Dermatology, May 2019;180(5):977-978. PMID: 31025743.
11. Reddy SP, Lee EB, Wu JJ. Apremilast and phototherapy for a psoriasis patient with human immunodeficiency virus. Cutis, May 2019;103(5):E6-E7. PMID: 31233584.
12. Lee EB, Pithadia DJ, Reynolds KA, Reddy SP, Egeberg A, Wu JJ. Real-world drug survival of ixekizumab for psoriasis. Journal of the American Academy of Dermatology, July 2019;81(1):270-272. PMID: 30690047.
13. Wu JJ, Veverka KA, Lu M, Armstrong AW. Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. Journal of Dermatological Treatment, August 2019;30(5):454-460. PMID: 30307343.
14. Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. Translating the 2019 AAD-NPF guidelines of care for the management of psoriasis with biologics to clinical practice. Cutis, August 2019;104(2S):12-16. PMID: 31634385.
15. Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, Armstrong AW, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselican M, Kivelevitch D, Korman NJ, Kroshinsky D, Leonardi CL, Lichten J, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. Journal of the American Academy of Dermatology, September 2019;81(3):775-804. PMID: 31351884.
16. Reynolds KA, Pithadia DJ, Lee EB, Wu JJ. YouTube videos on oral systemic therapies for psoriasis: a cross-sectional analysis. Journal of Dermatological Treatment, September 2019;30(6):549. PMID: 30457412.
17. Smith MP, Ly K, Thibodeaux Q, Weerasinghe T, Wu JJ, Yosipovitch G, Bhutani T, Liao W. Emerging methods to objectively assess pruritus in atopic dermatitis. Dermatology and Therapy, September 2019;9(3):407-420. PMID: 31256388.
18. Smith MP, Ly K, Thibodeaux Q, Weerasinghe T, Beck K, Shankle L, Armstrong AW, Boas M, Bridges A, Doris F, Gelfand JM, Lafoy B, Orbai AM, Takeshita J, Truman S, Wan MT, Wu JJ, Siegel MP, Bell SJ, Bhutani T, Liao W. Factors influencing sleep difficulty and sleep quantity in the Citizen Pscientist Psoriatic Cohort. Dermatology and Therapy, September 2019;9(3):511-523. PMID: 31177381.
19. Andersen YM, Wu JJ, Thyssen JP, Egeberg A. Chronological order of appearance of immune mediated inflammatory diseases relative to diagnosis of psoriasis. Journal of the American Academy of Dermatology, December 2019;81(6):1283-1291. PMID: 31009673.
20. Lee EB, Pithadia DJ, Reynolds KA, Wu JJ. ICER psoriasis update 2018: what it means for dermatologists treating moderate-to-severe plaque psoriasis. Journal of Dermatological Treatment, December 2019;30(8):772-774. PMID: 30668188.
21. Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselican M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Journal of the American Academy of Dermatology, January 2020;82(1):161-201. PMID: 31703821.
22. Wu JJ, Pelletier C, Ung B, Tian M. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis. Current Medical Research & Opinion, January 2020;36(1):169-176. PMID: 31517542.
23. Natsis NE, Merola JF, Weinberg JM, Wu JJ, Orbai AM, Bagel J, Gottlieb AB. Treatment of Medicare patients with moderate-to-severe psoriasis who cannot afford biologics or apremilast. American Journal of Clinical Dermatology, February 2020;21(1):109-117. PMID: 31452091.
24. Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. Psoriasis-associated itch: etiology, assessment, impact, and management. Journal of Dermatological Treatment, February 2020;31(1):18-26. PMID: 30663443.
25. Lee EB, Amin M, Wu JJ. TNF inhibitors may reduce cardiovascular morbidity in psoriasis patients. Cutis, February 2020;105(2):60-61. PMID: 32186527.
26. Alinaghi F, Tekin H, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease – a systematic review and meta-analysis. Journal of Crohn’s and Colitis, March 2020;14(3):351-360. PMID: 31504363.
27. Hsu S, Green LJ, Lebwohl MG, Wu JJ, Blauvelt A, Jacobson AA. Comparable efficacy and safety of brodalumab in obese and non-obese patients with psoriasis: analysis of 2 randomized controlled trials. British Journal of Dermatology, April 2020;182(4):880-888. PMID: 31276189.
28. Reynolds KA, Pithadia DJ, Lee EB, Han G, Wu JJ. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review. Expert Opinion On Drug Safety, April 2020;19(4):459-466. PMID: 32116071.
29. Blauvelt A, Wu JJ, Armstrong A, Menter A, Liu C, Jacobson A. Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes. Journal of Drugs in Dermatology, May 2020;19(5):487-492. PMID: 32484628.
30. Wu JJ, Pelletier C, Ung B, Tian M, Khilfeh I, Curtis JR. Treatment switch patterns and healthcare costs in biologic-naive patients with psoriatic arthritis. Advances in Therapy, May 2020;37(5):2098-2115. PMID: 32141018.
31. Silverberg JI, Yosipovitch G, Simpson EL, Kim BS, Wu JJ, Eckert L, Guillemin I, Chen Z, Ardeleanu M, Bansal A, Kaur M, Rossi AB, Graham NM, Patel N, Gadkari A. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate-to-severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 & SOLO 2, AD ADOL, and CHRONOS. Journal of the American Academy of Dermatology, June 2020;82(6):1328-1336. PMID: 32135208.
32. Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselican M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani R, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management of psoriasis with systemic non-biological therapies. Journal of the American Academy of Dermatology, June 2020;82(6):1445-1486. PMID: 32119894.
33. Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatology, June 2020;156(6):649-658. PMID: 32267471.
34. Thyssen JP, Halling-Sønderby AS, Wu JJ, Egeberg A. Pain severity and use of analgesic medication in adults with atopic dermatitis. British Journal of Dermatology, June 2020;182(6):1430-1436. PMID: 31556099.
35. Lee EB, Reynolds KA, Pithadia DJ, Egeberg A, Wu JJ. Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review. Journal of Dermatological Treatment, June 2020;31(4):342-343. PMID: 30957586.
36. Wu KK, Lee MP, Lee EB, Wu JJ. Risk of herpes zoster during IL-17 inhibitor therapy for psoriasis and other inflammatory conditions. Journal of Dermatological Treatment, June 2020;31(4):359-365. PMID: 30900514.
37. Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. A cross-sectional study of YouTube videos as a source of patient information for topical psoriasis therapies. Journal of Dermatological Treatment, June 2020;31(4):366-369. PMID: 30885022.
38. Wu JJ, Merola JF, Feldman SR, Menter A, Lebwohl M. Treatment of psoriasis with secukinumab in challenging patient scenarios: a review of the available evidence. Dermatology and Therapy, June 2020;10(3):351-364. PMID: 32242325.
39. Wu JJ, Hansen JB, Patel DS, Nyholm N, Veverka KA, Swensen AR. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: A matching-adjusted indirect comparative analysis. Journal of Medical Economics, June 2020;23(6):641-649. PMID: 31985301.
40. Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ. Risk of tuberculosis reactivation during IL-17 inhibitor therapy for psoriasis: a systematic review. Journal of the European Academy of Dermatology and Venereology, July 2020;34(7):1449-1456. PMID: 32012384.
41. Reynolds KA, Pithadia DJ, Lee EB, Liao W, Wu JJ. Safety and effectiveness of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis. American Journal of Clinical Dermatology, August 2020;21(4):483-491. PMID: 32048187.
42. Kearns DG, Uppal S, Chat VS, Han G, Wu JJ. Translating the 2019 AAD-NPF guidelines of care for the management of psoriasis with phototherapy. Cutis, August 2020;106(2):82-86. PMID: 32941553.
43. Lebwohl M, Leonardi C, Wu JJ, Yamauchi P, Rawnsley N, Merchant M, Alexander B, Jacobson A. One-year pharmacovigilance update of brodalumab. Journal of Drugs in Dermatology, August 2020;19(8):807-808. PMID: 32845586.
44. Wu JJ, Pelletier C, Ung B, Tian M, Khilfeh I, Curtis JR. Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics. Journal of Comparative Effectiveness Research, August 2020;9(11):767-779. PMID: 32638609.
45. Kearns DG, Uppal SK, Chat VS, Wu JJ. Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic. Journal of the American Academy of Dermatology, September 2020;83(3):e251-e252. PMID: 32534081.
46. Kearns DG, Chat VS, Uppal SK, Wu JJ. Applying to dermatology residency during the COVID-19 pandemic. Journal of the American Academy of Dermatology, October 2020;83(4):1214-1215. PMID: 32652192.
47. Wu JJ, Lin CY, Goldblum O, Zbrozek A, Comer BS, Burge R, Augustin M, Feldman SR. Efficacious psoriasis treatment improves patients' work productivity. Journal of the European Academy of Dermatology and Venereology, October 2020;34(10):e593-e596. PMID: 32277526.
48. Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. A cross-sectional study of YouTube videos as a source of patient information about phototherapy and excimer laser for psoriasis. Journal of Dermatological Treatment, November 2020;31(7):707-710. PMID: 30963794.
49. Reynolds KA, Pithadia DJ, Lee EB, Wu JJ. Treatments for inverse psoriasis: a systematic review. Journal of Dermatological Treatment, December 2020;31(8):786-793. PMID: 31100992.
50. Pithadia DJ, Reynolds KA, Lee EB, Liao W, Wu JJ. Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. Therapeutic Advances in Chronic Disease, Published online August 12, 2019. PMID: 31448070.
51. Puig L, Wu JJ, Gooderham MJ, You Y, Shen YK, Randazzo B, Kerdel F. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. Journal of Drugs in Dermatology, Published online October 15, 2019.PMID: 31613178.
52. Reynolds KA, Pithadia DJ, Lee EB, Liao W, Wu JJ, A systematic review of treatment strategies for erythrodermic psoriasis. Journal of Dermatological Treatment, Published online November 4, 2019. PMID: 31682547.
53. Chat VS, Kearns DG, Uppal SK, Wu JJ. Risk of atypical mycobacterial infections in psoriasis patients during IL-17 inhibitor therapy. Journal of Dermatological Treatment, Published online November 5, 2019. PMID: 31689137.
54. Kearns DG, Zang PD, Chat VS, Han G, Wu JJ. Review of treatments for generalized pustular psoriasis. Journal of Dermatological Treatment, Published online November 7, 2019. PMID: 31697211.
55. Amin M, Lee EB, Tsai TF, Wu JJ. Psoriasis and co-morbidity. Acta Dermato-Venereologica, Published online January 23, 2020. PMID: 31971602.
56. Gerdes S, Velasco M, Wu JJ, Hubo M, Veverka KA. Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE). Journal of Dermatological Treatment, Published online January 28, 2020. PMID: 31986945.
57. Hoegsberg T, Iversen L, Lange MM, Bissonette R, Carvalho AVE, van de Kerkhof PC, Kirby B, Kleyn CE, van der Walt JM, Wu JJ, Lynde CW. Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites. Journal of Dermatological Treatment, Published online January 30, 2020. PMID: 31996058.
58. Wu JJ, Jia X, Zhao Y, Carrico J, Brodtkorb T, Mendelsohn A, Lowry S, Feldman SR, Armstrong A. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. Journal of Dermatological Treatment, Published online April 1, 2020. PMID: 32233828.
59. Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. Dupilumab for atopic dermatitis: what are patients learning on YouTube? Journal of Dermatological Treatment, Published online April 11, 2020. PMID: 32281445.
60. Ghamrawi RI, Ghiam N, Wu JJ. Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review. Journal of Dermatological Treatment, Published online May 25, 2020. PMID: 32419531.
61. Kearns DG, Uppal SK, Chat VS, Wu JJ. Use of systemic therapies for psoriasis in the COVID-19 era. Journal of Dermatological Treatment, Published online May 27, 2020. PMID: 32459567.
62. Uppal SK, Kearns DG, Chat VS, Han G, Wu JJ. Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis. Journal of Dermatological Treatment, Published online June 8, 2020. PMID: 32507066.
63. Chat VS, Uppal SK, Kearns DG, Wu JJ. Clinical management of psoriasis patients during the COVID-19 pandemic. Journal of Dermatological Treatment, Published online June 22, 2020. PMID: 32568009.
64. Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn AM, Lowry S, Feldman S, Wu JJ, Armstrong AW. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. Journal of Dermatological Treatment, Published online June 30, 2020. PMID: 32602762.
65. Kearns DG, Chat VS, Uppal S, Wu JJ. Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic. Journal of the American Academy of Dermatology, Published online July 28, 2020. PMID: 32735966.
66. Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani R, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselican M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober BE, Wu JJ, Hariharan V, Menter A. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal of the American Academy of Dermatology, Published online July 30, 2020. PMID: 32738429.
67. Wu JJ, Schrader A, McLean RR, Valdecantos W, Etzel C, Singh R. Improvement in body surface area is associated with better quality of life among patients with psoriasis in the Corrona Psoriasis Registry. Journal of the American Academy of Dermatology, Published online August 13, 2020. PMID: 32798582.
68. Tran B, Wu JJ, Ratner D, Han G. Topical scar treatment products for wounds: a systematic review. Dermatologic Surgery, Published online September 8, 2020. PMID: 32932267.
69. Feagan B, Marabani M, Wu JJ, Faccin F, Spronk C, Castañeda-Hernández G. The challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of current evidence. Advances in Therapy, Published online September 10, 2020. PMID: 32910420.
70. Ghamrawi RI, Ghiam N, Wu JJ. Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review. Journal of Dermatological Treatment, Journal of Dermatological Treatment, Published online September 22, 2020. PMID: 32962478.
71. Chat VS, Uppal S, Kearns DG, Wu JJ. Translating the 2019 AAD-NPF guidelines of care for psoriasis with attention to comorbidities. Cutis, In press for August 2020.
72. Lee MP, Wu KK, Lee EB, Wu JJ. Risk of deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis. Cutis, In press for October 2020.
73. Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. Overview of the 2019 joint American Academy of Dermatology and National Psoriasis Foundation guidelines for the management of psoriasis in pediatric patients. Cutis, In press for November 2020.
74. Chat VS, Uppal S, Kearns DG, Han G, Wu JJ. Translating the 2020 AAD-NPF guidelines for psoriasis management with systemic non-biologics to clinical practice. Cutis, Accepted June 3, 2020, In press for February 2021.
75. Rivera-Oyola R, Stanger R, Litchman GH, Thibodeaux Q, Koo J, Fried R, Goldenberg G, Han G, Hsu S, Kircik L, Knuckles M, Murina A, Weinberg J, Wu JJ, Lebwohl M. The use of brodalumab in three patients with psoriasis and psychiatric comorbidities. Journal of Clinical and Aesthetic Dermatology, Accepted March 9, 2020.
76. Uppal SK, Chat VS, Kearns DG, Wu JJ. Topical agents currently in phase II or phase III trials for atopic dermatitis. Journal of Drugs in Dermatology, Accepted May 28, 2020.
77. Ivanic MG, Naderi-Azad S, Walia S, Han G, Wu JJ. Management of psoriasis with biologics in clinical practice: an update for 2020. Cutis, Accepted July 2, 2020.
78. Uppal SK, Kearns DG, Chat VS, Wu JJ. The role of dermatologists as social media contributors during the COVID-19 pandemic. Cutis, Accepted July 15, 2020.
79. Uppal SK, Kearns DG, Chat VS, Wu JJ. Ruxolitinib cream for the treatment of vitiligo. The Lancet, Accepted August 19, 2020.
80. Uppal SK, Chat VS, Kearns DG, Wu JJ. Abrocitinib for atopic dermatitis. The Lancet, Accepted September 8, 2020.
81. Kearns DG, Chat VS, Uppal SK, Wu JJ. Reply to letter to the editor regarding: “Applying to dermatology residency during the COVID-19 pandemic.” Journal of the American Academy of Dermatology, Accepted September 23, 2020.
82. Gottlieb AB, Wu JJ, Griffiths CEM, Marfo K, Muscianisi E, Meng X, Frueh J, Lebwohl M. Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials. Journal of Dermatological Treatment, Accepted September 23, 2020.
83. Thatiparthi A, Liu J, Martin A, Wu JJ. A response to ‘male balding is a major risk factor for severe COVID-19'. Journal of the American Academy of Dermatology, Accepted October 5, 2020.
84. Walia S, Ivanic MG, Jafri ZA, Wu JJ. Skin cancer screening and prevention during the COVID-19 pandemic. Cutis, Accepted October 8, 2020.
85. Uppal S, Kearns DG, Chat VS, Wu JJ. Reply: Understanding the potential role of abrocitinib in the time of SARS-CoV-2. Journal of Drugs in Dermatology, Accepted October 8, 2020.
1. Wu JJ, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Arikan D, Fleischer A, Guérin A, Ganguli A. Adverse medical conditions across treatment options in patients with psoriasis: a claims-based analysis. Journal of Drugs in Dermatology, November 2018;17(11):1211-1218. PMID: 30500143.
2. Lee EB, Wu KK, Lee MP, Bhutani T, Wu JJ. Psoriasis risk factors and triggers. Cutis, November 2018;102(5S):18-20. PMID: 30566552.
3. Lee EB, Reynolds KA, Pithadia DJ, Wu JJ. Appearance of lentigines in psoriasis patient treated with guselkumab. Dermatology Online Journal, January 2019;25(1). PMID: 30710906.
4. Lee EB, Amin M, Duan L, Egeberg A, Wu JJ. Risk for appendicitis, cholecystitis, or diverticulitis in patients with psoriasis. Cutis, March 2019;103(3):175-179;E1;E2. PMID: 31039227.
5. Reynolds KA, Pithadia DJ, Lee EB, Wu JJ. A cross-sectional study of YouTube videos about psoriasis biologics. International Journal of Dermatology, March 2019;58(3):e61-e62. PMID: 30478827.
6. Strober BE, van der Walt JM, Armstrong AW, Boucier M, Carvalho AV, Chouela E, Cohen AD, Cruz C, Ellis CN, Finlay AY, Gottlieb AB, Gudjonsson JE, Iversen L, Kleyn CE, Leonardi CL, Lynde CW, Ryan C, Theng CT, Valenzuela F, Vender R, Wu JJ, Young HS, Kimball AB. Clinical goals and barriers to effective psoriasis care. Dermatology and Therapy, March 2019;9(1):5-18. PMID: 30578464.
7. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, April 2019;80(4):1029-1072. PMID: 30772098.
8. Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology, April 2019;80(4):1073-1113. PMID: 30772097.
9. Wu JJ, Pelletier C, Ung B, Tian M. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis. Journal of Medical Economics, April 2019;22(4):365-371. PMID: 30652520.
10. Lee EB, Wu JJ. Safety of long-term IL-23 inhibition in psoriasis patients. British Journal of Dermatology, May 2019;180(5):977-978. PMID: 31025743.
11. Reddy SP, Lee EB, Wu JJ. Apremilast and phototherapy for a psoriasis patient with human immunodeficiency virus. Cutis, May 2019;103(5):E6-E7. PMID: 31233584.
12. Lee EB, Pithadia DJ, Reynolds KA, Reddy SP, Egeberg A, Wu JJ. Real-world drug survival of ixekizumab for psoriasis. Journal of the American Academy of Dermatology, July 2019;81(1):270-272. PMID: 30690047.
13. Wu JJ, Veverka KA, Lu M, Armstrong AW. Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. Journal of Dermatological Treatment, August 2019;30(5):454-460. PMID: 30307343.
14. Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. Translating the 2019 AAD-NPF guidelines of care for the management of psoriasis with biologics to clinical practice. Cutis, August 2019;104(2S):12-16. PMID: 31634385.
15. Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, Armstrong AW, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselican M, Kivelevitch D, Korman NJ, Kroshinsky D, Leonardi CL, Lichten J, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. Journal of the American Academy of Dermatology, September 2019;81(3):775-804. PMID: 31351884.
16. Reynolds KA, Pithadia DJ, Lee EB, Wu JJ. YouTube videos on oral systemic therapies for psoriasis: a cross-sectional analysis. Journal of Dermatological Treatment, September 2019;30(6):549. PMID: 30457412.
17. Smith MP, Ly K, Thibodeaux Q, Weerasinghe T, Wu JJ, Yosipovitch G, Bhutani T, Liao W. Emerging methods to objectively assess pruritus in atopic dermatitis. Dermatology and Therapy, September 2019;9(3):407-420. PMID: 31256388.
18. Smith MP, Ly K, Thibodeaux Q, Weerasinghe T, Beck K, Shankle L, Armstrong AW, Boas M, Bridges A, Doris F, Gelfand JM, Lafoy B, Orbai AM, Takeshita J, Truman S, Wan MT, Wu JJ, Siegel MP, Bell SJ, Bhutani T, Liao W. Factors influencing sleep difficulty and sleep quantity in the Citizen Pscientist Psoriatic Cohort. Dermatology and Therapy, September 2019;9(3):511-523. PMID: 31177381.
19. Andersen YM, Wu JJ, Thyssen JP, Egeberg A. Chronological order of appearance of immune mediated inflammatory diseases relative to diagnosis of psoriasis. Journal of the American Academy of Dermatology, December 2019;81(6):1283-1291. PMID: 31009673.
20. Lee EB, Pithadia DJ, Reynolds KA, Wu JJ. ICER psoriasis update 2018: what it means for dermatologists treating moderate-to-severe plaque psoriasis. Journal of Dermatological Treatment, December 2019;30(8):772-774. PMID: 30668188.
21. Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselican M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Journal of the American Academy of Dermatology, January 2020;82(1):161-201. PMID: 31703821.
22. Wu JJ, Pelletier C, Ung B, Tian M. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis. Current Medical Research & Opinion, January 2020;36(1):169-176. PMID: 31517542.
23. Natsis NE, Merola JF, Weinberg JM, Wu JJ, Orbai AM, Bagel J, Gottlieb AB. Treatment of Medicare patients with moderate-to-severe psoriasis who cannot afford biologics or apremilast. American Journal of Clinical Dermatology, February 2020;21(1):109-117. PMID: 31452091.
24. Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. Psoriasis-associated itch: etiology, assessment, impact, and management. Journal of Dermatological Treatment, February 2020;31(1):18-26. PMID: 30663443.
25. Lee EB, Amin M, Wu JJ. TNF inhibitors may reduce cardiovascular morbidity in psoriasis patients. Cutis, February 2020;105(2):60-61. PMID: 32186527.
26. Alinaghi F, Tekin H, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease – a systematic review and meta-analysis. Journal of Crohn’s and Colitis, March 2020;14(3):351-360. PMID: 31504363.
27. Hsu S, Green LJ, Lebwohl MG, Wu JJ, Blauvelt A, Jacobson AA. Comparable efficacy and safety of brodalumab in obese and non-obese patients with psoriasis: analysis of 2 randomized controlled trials. British Journal of Dermatology, April 2020;182(4):880-888. PMID: 31276189.
28. Reynolds KA, Pithadia DJ, Lee EB, Han G, Wu JJ. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review. Expert Opinion On Drug Safety, April 2020;19(4):459-466. PMID: 32116071.
29. Blauvelt A, Wu JJ, Armstrong A, Menter A, Liu C, Jacobson A. Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes. Journal of Drugs in Dermatology, May 2020;19(5):487-492. PMID: 32484628.
30. Wu JJ, Pelletier C, Ung B, Tian M, Khilfeh I, Curtis JR. Treatment switch patterns and healthcare costs in biologic-naive patients with psoriatic arthritis. Advances in Therapy, May 2020;37(5):2098-2115. PMID: 32141018.
31. Silverberg JI, Yosipovitch G, Simpson EL, Kim BS, Wu JJ, Eckert L, Guillemin I, Chen Z, Ardeleanu M, Bansal A, Kaur M, Rossi AB, Graham NM, Patel N, Gadkari A. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate-to-severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 & SOLO 2, AD ADOL, and CHRONOS. Journal of the American Academy of Dermatology, June 2020;82(6):1328-1336. PMID: 32135208.
32. Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselican M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani R, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management of psoriasis with systemic non-biological therapies. Journal of the American Academy of Dermatology, June 2020;82(6):1445-1486. PMID: 32119894.
33. Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatology, June 2020;156(6):649-658. PMID: 32267471.
34. Thyssen JP, Halling-Sønderby AS, Wu JJ, Egeberg A. Pain severity and use of analgesic medication in adults with atopic dermatitis. British Journal of Dermatology, June 2020;182(6):1430-1436. PMID: 31556099.
35. Lee EB, Reynolds KA, Pithadia DJ, Egeberg A, Wu JJ. Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review. Journal of Dermatological Treatment, June 2020;31(4):342-343. PMID: 30957586.
36. Wu KK, Lee MP, Lee EB, Wu JJ. Risk of herpes zoster during IL-17 inhibitor therapy for psoriasis and other inflammatory conditions. Journal of Dermatological Treatment, June 2020;31(4):359-365. PMID: 30900514.
37. Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. A cross-sectional study of YouTube videos as a source of patient information for topical psoriasis therapies. Journal of Dermatological Treatment, June 2020;31(4):366-369. PMID: 30885022.
38. Wu JJ, Merola JF, Feldman SR, Menter A, Lebwohl M. Treatment of psoriasis with secukinumab in challenging patient scenarios: a review of the available evidence. Dermatology and Therapy, June 2020;10(3):351-364. PMID: 32242325.
39. Wu JJ, Hansen JB, Patel DS, Nyholm N, Veverka KA, Swensen AR. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: A matching-adjusted indirect comparative analysis. Journal of Medical Economics, June 2020;23(6):641-649. PMID: 31985301.
40. Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ. Risk of tuberculosis reactivation during IL-17 inhibitor therapy for psoriasis: a systematic review. Journal of the European Academy of Dermatology and Venereology, July 2020;34(7):1449-1456. PMID: 32012384.
41. Reynolds KA, Pithadia DJ, Lee EB, Liao W, Wu JJ. Safety and effectiveness of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis. American Journal of Clinical Dermatology, August 2020;21(4):483-491. PMID: 32048187.
42. Kearns DG, Uppal S, Chat VS, Han G, Wu JJ. Translating the 2019 AAD-NPF guidelines of care for the management of psoriasis with phototherapy. Cutis, August 2020;106(2):82-86. PMID: 32941553.
43. Lebwohl M, Leonardi C, Wu JJ, Yamauchi P, Rawnsley N, Merchant M, Alexander B, Jacobson A. One-year pharmacovigilance update of brodalumab. Journal of Drugs in Dermatology, August 2020;19(8):807-808. PMID: 32845586.
44. Wu JJ, Pelletier C, Ung B, Tian M, Khilfeh I, Curtis JR. Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics. Journal of Comparative Effectiveness Research, August 2020;9(11):767-779. PMID: 32638609.
45. Kearns DG, Uppal SK, Chat VS, Wu JJ. Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic. Journal of the American Academy of Dermatology, September 2020;83(3):e251-e252. PMID: 32534081.
46. Kearns DG, Chat VS, Uppal SK, Wu JJ. Applying to dermatology residency during the COVID-19 pandemic. Journal of the American Academy of Dermatology, October 2020;83(4):1214-1215. PMID: 32652192.
47. Wu JJ, Lin CY, Goldblum O, Zbrozek A, Comer BS, Burge R, Augustin M, Feldman SR. Efficacious psoriasis treatment improves patients' work productivity. Journal of the European Academy of Dermatology and Venereology, October 2020;34(10):e593-e596. PMID: 32277526.
48. Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. A cross-sectional study of YouTube videos as a source of patient information about phototherapy and excimer laser for psoriasis. Journal of Dermatological Treatment, November 2020;31(7):707-710. PMID: 30963794.
49. Reynolds KA, Pithadia DJ, Lee EB, Wu JJ. Treatments for inverse psoriasis: a systematic review. Journal of Dermatological Treatment, December 2020;31(8):786-793. PMID: 31100992.
50. Pithadia DJ, Reynolds KA, Lee EB, Liao W, Wu JJ. Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. Therapeutic Advances in Chronic Disease, Published online August 12, 2019. PMID: 31448070.
51. Puig L, Wu JJ, Gooderham MJ, You Y, Shen YK, Randazzo B, Kerdel F. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. Journal of Drugs in Dermatology, Published online October 15, 2019.PMID: 31613178.
52. Reynolds KA, Pithadia DJ, Lee EB, Liao W, Wu JJ, A systematic review of treatment strategies for erythrodermic psoriasis. Journal of Dermatological Treatment, Published online November 4, 2019. PMID: 31682547.
53. Chat VS, Kearns DG, Uppal SK, Wu JJ. Risk of atypical mycobacterial infections in psoriasis patients during IL-17 inhibitor therapy. Journal of Dermatological Treatment, Published online November 5, 2019. PMID: 31689137.
54. Kearns DG, Zang PD, Chat VS, Han G, Wu JJ. Review of treatments for generalized pustular psoriasis. Journal of Dermatological Treatment, Published online November 7, 2019. PMID: 31697211.
55. Amin M, Lee EB, Tsai TF, Wu JJ. Psoriasis and co-morbidity. Acta Dermato-Venereologica, Published online January 23, 2020. PMID: 31971602.
56. Gerdes S, Velasco M, Wu JJ, Hubo M, Veverka KA. Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE). Journal of Dermatological Treatment, Published online January 28, 2020. PMID: 31986945.
57. Hoegsberg T, Iversen L, Lange MM, Bissonette R, Carvalho AVE, van de Kerkhof PC, Kirby B, Kleyn CE, van der Walt JM, Wu JJ, Lynde CW. Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites. Journal of Dermatological Treatment, Published online January 30, 2020. PMID: 31996058.
58. Wu JJ, Jia X, Zhao Y, Carrico J, Brodtkorb T, Mendelsohn A, Lowry S, Feldman SR, Armstrong A. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. Journal of Dermatological Treatment, Published online April 1, 2020. PMID: 32233828.
59. Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. Dupilumab for atopic dermatitis: what are patients learning on YouTube? Journal of Dermatological Treatment, Published online April 11, 2020. PMID: 32281445.
60. Ghamrawi RI, Ghiam N, Wu JJ. Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review. Journal of Dermatological Treatment, Published online May 25, 2020. PMID: 32419531.
61. Kearns DG, Uppal SK, Chat VS, Wu JJ. Use of systemic therapies for psoriasis in the COVID-19 era. Journal of Dermatological Treatment, Published online May 27, 2020. PMID: 32459567.
62. Uppal SK, Kearns DG, Chat VS, Han G, Wu JJ. Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis. Journal of Dermatological Treatment, Published online June 8, 2020. PMID: 32507066.
63. Chat VS, Uppal SK, Kearns DG, Wu JJ. Clinical management of psoriasis patients during the COVID-19 pandemic. Journal of Dermatological Treatment, Published online June 22, 2020. PMID: 32568009.
64. Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn AM, Lowry S, Feldman S, Wu JJ, Armstrong AW. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. Journal of Dermatological Treatment, Published online June 30, 2020. PMID: 32602762.
65. Kearns DG, Chat VS, Uppal S, Wu JJ. Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic. Journal of the American Academy of Dermatology, Published online July 28, 2020. PMID: 32735966.
66. Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani R, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselican M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober BE, Wu JJ, Hariharan V, Menter A. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal of the American Academy of Dermatology, Published online July 30, 2020. PMID: 32738429.
67. Wu JJ, Schrader A, McLean RR, Valdecantos W, Etzel C, Singh R. Improvement in body surface area is associated with better quality of life among patients with psoriasis in the Corrona Psoriasis Registry. Journal of the American Academy of Dermatology, Published online August 13, 2020. PMID: 32798582.
68. Tran B, Wu JJ, Ratner D, Han G. Topical scar treatment products for wounds: a systematic review. Dermatologic Surgery, Published online September 8, 2020. PMID: 32932267.
69. Feagan B, Marabani M, Wu JJ, Faccin F, Spronk C, Castañeda-Hernández G. The challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of current evidence. Advances in Therapy, Published online September 10, 2020. PMID: 32910420.
70. Ghamrawi RI, Ghiam N, Wu JJ. Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review. Journal of Dermatological Treatment, Journal of Dermatological Treatment, Published online September 22, 2020. PMID: 32962478.
71. Chat VS, Uppal S, Kearns DG, Wu JJ. Translating the 2019 AAD-NPF guidelines of care for psoriasis with attention to comorbidities. Cutis, In press for August 2020.
72. Lee MP, Wu KK, Lee EB, Wu JJ. Risk of deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis. Cutis, In press for October 2020.
73. Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. Overview of the 2019 joint American Academy of Dermatology and National Psoriasis Foundation guidelines for the management of psoriasis in pediatric patients. Cutis, In press for November 2020.
74. Chat VS, Uppal S, Kearns DG, Han G, Wu JJ. Translating the 2020 AAD-NPF guidelines for psoriasis management with systemic non-biologics to clinical practice. Cutis, Accepted June 3, 2020, In press for February 2021.
75. Rivera-Oyola R, Stanger R, Litchman GH, Thibodeaux Q, Koo J, Fried R, Goldenberg G, Han G, Hsu S, Kircik L, Knuckles M, Murina A, Weinberg J, Wu JJ, Lebwohl M. The use of brodalumab in three patients with psoriasis and psychiatric comorbidities. Journal of Clinical and Aesthetic Dermatology, Accepted March 9, 2020.
76. Uppal SK, Chat VS, Kearns DG, Wu JJ. Topical agents currently in phase II or phase III trials for atopic dermatitis. Journal of Drugs in Dermatology, Accepted May 28, 2020.
77. Ivanic MG, Naderi-Azad S, Walia S, Han G, Wu JJ. Management of psoriasis with biologics in clinical practice: an update for 2020. Cutis, Accepted July 2, 2020.
78. Uppal SK, Kearns DG, Chat VS, Wu JJ. The role of dermatologists as social media contributors during the COVID-19 pandemic. Cutis, Accepted July 15, 2020.
79. Uppal SK, Kearns DG, Chat VS, Wu JJ. Ruxolitinib cream for the treatment of vitiligo. The Lancet, Accepted August 19, 2020.
80. Uppal SK, Chat VS, Kearns DG, Wu JJ. Abrocitinib for atopic dermatitis. The Lancet, Accepted September 8, 2020.
81. Kearns DG, Chat VS, Uppal SK, Wu JJ. Reply to letter to the editor regarding: “Applying to dermatology residency during the COVID-19 pandemic.” Journal of the American Academy of Dermatology, Accepted September 23, 2020.
82. Gottlieb AB, Wu JJ, Griffiths CEM, Marfo K, Muscianisi E, Meng X, Frueh J, Lebwohl M. Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials. Journal of Dermatological Treatment, Accepted September 23, 2020.
83. Thatiparthi A, Liu J, Martin A, Wu JJ. A response to ‘male balding is a major risk factor for severe COVID-19'. Journal of the American Academy of Dermatology, Accepted October 5, 2020.
84. Walia S, Ivanic MG, Jafri ZA, Wu JJ. Skin cancer screening and prevention during the COVID-19 pandemic. Cutis, Accepted October 8, 2020.
85. Uppal S, Kearns DG, Chat VS, Wu JJ. Reply: Understanding the potential role of abrocitinib in the time of SARS-CoV-2. Journal of Drugs in Dermatology, Accepted October 8, 2020.